The FIDELIO-DKD and FIGARO-DKD trials, as well as FIDELITY, demonstrated a beneficial effect of MR antagonism by finerenone on renal and cardiovascular outcomes across patients with CKD and T2D [20,21,22]. Here, NR3C2 is linked to diabetic kidney disease.